Company news

Lyell Immunopharma, Inc. news in 2024

Lyell Immunopharma, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

December 8, 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

November 6, 2024

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

November 4, 2024

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

October 30, 2024

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

October 23, 2024

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 3, 2024

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

September 23, 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

August 6, 2024

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

June 25, 2024

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 6, 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

May 5, 2024

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

March 4, 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

February 27, 2024

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Decks in 2024